Due to a worldwide increase in demand for the Gardasil 9 vaccine, used to prevent Human Papillomavirus (HPV), stocks of this vaccine are currently limited in Belgium. This limited availability has been extended and should continue until September 2020. The Federal Agency for Medicines and Health Products (FAMHP) has updated the recommendations for prescribers.
Coronavirus: extension and relaxing of measures taken by the FAMHP to avoid medicinal product shortages
On 1 April 2020, the FAMHP took steps to avoid a shortage of medicinal products. Some of these measures are to be further extended by one month, while others have been lifted.
On 1 April 2020, the FAMHP took steps to avoid a shortage of medicinal products. These actions will now be extended by one month until 1 June 2020.
Stocks of essential medicinal products to treat COVID-19 patients in hospital are being closely monitored. There are currently solutions and alternatives for all medicinal products necessary for the treatment of COVID-19 patients in Belgium.
Coronavirus: joint statement from the FAMHP and the ABSYM/BVAS (Belgian association of unions for medical practitioners) responding to the concerns of healthcare professionals in the field
The FAMHP and the Belgian association of unions for medical practitioners (ABSYM/BVAS) met this Wednesday, 16 April 2020, in a constructive and sincere atmosphere. The FAMHP explained that its teams are working hard to resolve the difficulties that certain hospitals have faced in obtaining supplies of medicinal products since the start of the COVID-19 pandemic. The emergency aid service was able to resolve temporary shortages encountered by hospitals.
Sales of paracetamol in pharmacies have returned to normal. As a result, some of the measures taken by the FAMHP in mid-March have been softened. Pharmaceutical companies and wholesaler-distributors no longer need to apply quotas, except in the case of intravenous infusion. Delivery is, however, still limited to one box per patient.
As Belgium acts as a logistics platform for certain medicinal products, the ban on exports outside the EEA (European Economic Area) could result in other countries being needlessly prevented access to medicines. The export ban will be replaced by a notification requirement to the FAMHP. The FAMHP can still ban exports in the interest of Belgian patients.
Coronavirus: details of the measures taken by the FAMHP (Federal Agency for Medicines and Health Products of Belgium) to avoid drug shortages
The FAMHP has once again put in place a number of measures to avoid shortages of drugs during the coronavirus pandemic (COVID-19).
The FAMHP is monitoring the availability in Belgium of medication, including medication indispensable for treating COVID-19 inpatients, on a daily basis. In this context, the FAMHP is taking a number of measures to avoid medication shortages.
Certain stocks of over-the-counter medicinal products have been selling out rapidly in Belgian pharmacies recently as many citizens are stocking up on medicinal products. There are still sufficient wholesale stocks of medicinal products in Belgium, but to avoid a shortage, the FAMHP asks all citizens not to pointlessly stock up on medicinal products.